Etiology and Early Diagnosis of Neurodevelopmental Disorders

Neurodevelopmental Disorders Clinical Trial

Official title:

Etiology and Early Diagnosis of Neurodevelopmental Disorders

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02003170
• Other study ID #: 136272
• Status: Active, not recruiting
• Start date: May 2012
• Est. completion date: June 2024

Study information

• Verified date: November 2023
• Source: University of Arkansas
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.

Description:

Although neurodevelopmental disorders are very prevalent (for example Autism affects 1 out of every 88 children and dyslexia affects up to 15% of the population), the etiology of such disorders is not known. The purpose of this investigation is to identify common etiologies of neurodevelopmental disorders (i.e., speech delay, global developmental delay, autism) and determine if it is possible to find early indicators of the diagnosis and foster the potential for a better prognosis of these disorders. At this time the investigators examine patients with neurodevelopment disorders with various medical investigations, but the results of these investigations are not systematically evaluated. One of the goals of this research is to systematically examine this information in order to identify patterns of test abnormalities that have not been previously described. Another goal of this research is to identify the common etiologies typically identified by the medical evaluation, so we can further refine our approach. In addition, the investigators now have the ability to evaluate biological samples for biomarkers that have potential to be diagnostically useful.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 576
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Months to 99 Years

Eligibility

Inclusion Criteria:

• Neurodevelopmental delays

• Clinical visit at an Arkansas Children's Hospital Outpatient clinic

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Neurodevelopmental Disorders

Locations

Country	Name	City	State
United States	Arkansas Children's Hospital Research Institute	Little Rock	Arkansas

Sponsors (2)

Lead Sponsor	Collaborator
University of Arkansas	Arkansas Children's Hospital Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medical abnormalities associated with specific neurodevelopmental disorders	It is unknown if a specific set of biological abnormalities contribute to the formation of many types of neurodevelopmental disorders. The study is intended to identify the relationship between biological abnormalities and neurodevelopmental disorders	up to 7 years
Secondary	Biomarkers associated with neurodevelopmental disorders	It is unknown if a specific biomarkers are associated with specific neurodevelopmental disorders. The study is intended to identify the relationship between biological abnormalities and neurodevelopmental disorders	up to 7 years
Secondary	Treatments associated with neurodevelopmental disorders	Various behavioral and medical treatments are used for many types of neurodevelopmental disorders but the effectiveness for many of these treatments is not known. The study is intended to identify the relationship between biological abnormalities (and their treatments) and neurodevelopmental disorders	up to 7 years

External Links

•   To see a list of current clinical Trials at Arkansas Children's Hospital, click here!!